Certuity LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Certuity LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 170.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,810 shares of the biopharmaceutical company’s stock after purchasing an additional 95,068 shares during the period. Certuity LLC’s holdings in Pfizer were worth $4,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signet Investment Advisory Group Inc. raised its position in Pfizer by 3.5% during the fourth quarter. Signet Investment Advisory Group Inc. now owns 123,186 shares of the biopharmaceutical company’s stock valued at $3,268,000 after acquiring an additional 4,152 shares in the last quarter. Augustine Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $470,000. Reik & CO. LLC increased its holdings in shares of Pfizer by 29.0% during the 4th quarter. Reik & CO. LLC now owns 33,336 shares of the biopharmaceutical company’s stock valued at $883,000 after purchasing an additional 7,500 shares in the last quarter. Edmp Inc. lifted its stake in shares of Pfizer by 20.0% in the 4th quarter. Edmp Inc. now owns 13,532 shares of the biopharmaceutical company’s stock valued at $359,000 after purchasing an additional 2,252 shares during the period. Finally, Sovran Advisors LLC purchased a new stake in Pfizer during the fourth quarter worth $922,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.3 %

PFE opened at $25.53 on Wednesday. The firm has a market capitalization of $144.69 billion, a price-to-earnings ratio of 18.11, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company’s 50 day simple moving average is $26.28 and its two-hundred day simple moving average is $27.69. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the business posted $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.74%. Pfizer’s payout ratio is 121.99%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price target on shares of Pfizer in a report on Monday. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.